Abstract
The question of whether platinum-based adjuvant chemotherapy can improve outcomes in patients with early-stage epithelial ovarian cancer is an important one. We carried out a multicenter, open randomized trial to determine whether adjuvant chemotherapy would improve overall survival and prolong recurrence-free survival in women with early-stage epithelial ovarian cancer.
Original language | English |
---|---|
Pages (from-to) | 125-132 |
Number of pages | 8 |
Journal | Journal of the National Cancer Institute |
Volume | 95 |
Issue number | 2 |
DOIs | |
Publication status | Published - 15 Jan 2003 |
Keywords
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Carboplatin
- Carcinoma
- Chemotherapy, Adjuvant
- Cisplatin
- Confidence Intervals
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- International Cooperation
- Middle Aged
- Neoplasm Staging
- Observation
- Odds Ratio
- Ovarian Neoplasms
- Survival Analysis
- Treatment Outcome